MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.
“Parkinson’s Foundation gains an impassioned and proven leader with Howard Morgan as Chairman who will ensure we further our mission to make life better for people with Parkinson’s disease,” said outgoing board chairman John W. Kozyak, Esq., who will remain on the board. “Howard’s appointment marks a new chapter for the Foundation, which has been on a strong growth trajectory over the last few years. That is expected to accelerate with Howard as chairman of the board.”
Mr. Morgan, who has been active in private equity for more than 30 years, also has served as a board member of more than 20 businesses in the U.S., Europe and Australia. He currently serves on the boards of Industrea Acquisition Corp.; Oase Living Water; Harvard Business School Club of New York; Alexander Hamilton Institute; World Press Institute; and Friends of the Garvan Institute of Medical Research.
“I am honored to further my commitment to the Parkinson’s community and the Foundation by building on the success of my predecessor John Kozyak during his tenure as chairman of the Parkinson’s Foundation,” Morgan said. “The Foundation’s mission is personal for me, as my father lived with the disease for many years. I look forward to working with Andrew Albert as Vice Chair and the board to ensure a better life for everyone with Parkinson’s through investments in innovative research, improved clinical care, and expanded educational resources.”
Added Parkinson’s Foundation President and CEO John Lehr: “Howard is a proven leader with extensive business knowledge and experience. He has been an invaluable contributor to our board for more than a decade, working closely with John Kozyak and other board members to position the Foundation for its current phase of rapid growth. We are thrilled Howard is taking on this critical role as the Foundation expands its mission programs for greater impact on all those living with and affected by Parkinson’s disease.”
Established in 1957, the Parkinson’s Foundation has headquarters in New York and Miami with more than 100 staff members across the country and has an annual budget of $30 million. In addition to supporting Parkinson’s research and patient and caregiver education, the Foundation has a national and international network of over 40 Parkinson’s Centers of Excellence at hospitals and academic medical institutions, where medical teams who specialize in Parkinson’s disease work together to treat and set the highest standards of care for people living with Parkinson’s.
Officers of the 27-person board are effective July 1, 2018: Howard D. Morgan, Chair; Andrew B. Albert, Vice Chair; Constance W. Atwell, PhD, Secretary; Curt DeGreff, Assistant Secretary; Stephen Ackerman, Treasurer; J. Gordon Beckham, Jr., Assistant Treasurer; Kelly Sweeney, Chair, People with Parkinson’s Advisory Council. A complete list of the Parkinson’s Foundation’s board of directors is available at www.parkinson.org/board.
About the Parkinson’s Foundation
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).
About Parkinson’s Disease
Affecting nearly one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.